Shukra PharmaceuticalsBOM:524632 +7.57%66 Dividend Yield % is 0.03% as of Jul. 04, 2026, which is 94% below its 10-year median of 0.54. GuruFocus rates BOM:524632 with a GF Score™ of 66/100 and a GF Value™ of ₹8.69 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 518 Drug Manufacturers companies, Shukra Pharmaceuticals ranks worse than 99.42% on this metric.
As of today (2026-07-04), the Trailing Annual Dividend Yield of Shukra Pharmaceuticals is 0.03%.
The historical rank and industry rank for Shukra Pharmaceuticals's Dividend Yield % or its related term are showing as below:
BOM:524632'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.02 Med: 0.54 Max: 2.34
Current: 0.03
During the past 13 years, the highest Dividend Yield of Shukra Pharmaceuticals was 2.34%. The lowest was 0.02%. And the median was 0.54%.
BOM:524632's Dividend Yield % is ranked worse than 99.42% of 518
companies
in the Drug Manufacturers industry
Industry Median: 1.95
vs BOM:524632: 0.03
During the past 12 months, Shukra Pharmaceuticals's average Dividends Per Share Growth Rate was -90.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 49.40% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Shukra Pharmaceuticals was 49.40% per year. The lowest was 0.00% per year. And the median was 24.70% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Shukra Pharmaceuticals Dividend Yield % Related Terms
Shukra Pharmaceuticals Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Shukra Pharmaceuticals's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524632 vs ZTS, UTHR: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shukra Pharmaceuticals Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Shukra Pharmaceuticals's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Shukra Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 0.010000
2025-09-18
2025-09-18
0000-00-00
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shukra Pharmaceuticals (BOM:524632) has a Dividend Yield % of 0.03% as of Jul. 04, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Shukra Pharmaceuticals and its competitors. This is 94% below median its historical median of 0.54. Over the past decade, Shukra Pharmaceuticals' Dividend Yield % has ranged from 0.02 to 2.34. According to the industry distribution chart, Shukra Pharmaceuticals ranks #515 out of 518 companies in the Drug Manufacturers industry, placing it in the top 99.4%.
Is Shukra Pharmaceuticals' Dividend Yield % too high?
Shukra Pharmaceuticals' current Dividend Yield % of 0.03% is 94% below median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 2.34. The Drug Manufacturers industry median Dividend Yield % is 1.95. Shukra Pharmaceuticals' value of 0.03% is 98.5% below this industry median. Based on the distribution chart, Shukra Pharmaceuticals ranks #515 out of 518 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shukra Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shukra Pharmaceuticals ranks #515 out of 518 companies for Dividend Yield %. This places Shukra Pharmaceuticals in the lower half of its industry. The industry median Dividend Yield % is 1.95. Shukra Pharmaceuticals' value of 0.03% is 98.5% below this benchmark. Historically, Shukra Pharmaceuticals' own Dividend Yield % has ranged from 0.02 to 2.34 over the past decade. While the company's 10-year median is 0.54 vs. the industry median of 1.95, Shukra Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.95, based on 518 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shukra Pharmaceuticals's current Dividend Yield % of 0.03% is 98.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Shukra Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shukra Pharmaceuticals's current Dividend Yield % is 0.03%, which is 94% below median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (BOM:524632) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.69, compared to a current price of ₹31.68 — trading 264.6% above its estimated fair value. The current Dividend Yield % is 0.03%, which is 94% below median its 10-year median of 0.54 and 98.5% below the Drug Manufacturers industry median of 1.95. Shukra Pharmaceuticals' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Shukra Pharmaceuticals (BOM:524632), the current Dividend Yield % is 0.03% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?
Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹31.68 is trading 264.6% above its estimated GF Value™ of ₹8.69.
GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:524632:
Dividend Yield %: 0.03% (94% below median its 10-year median of 0.54)
GF Value™: ₹8.69 vs. price of ₹31.68 (264.6% above fair value)
Industry Position: 98.5% below the Drug Manufacturers median (#515 of 518)
No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
66GF Score
Get the complete analysis for BOM:524632
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524632 has been successfully added to your 
